Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application

Starting soon · Not applicable

Conditions studied: Severe High Altitude Pulmonary Edema, Severe High Altitude Cerebral Edema

In brief

This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.

Key facts

Study ID: NCT07639931
Run by: Tibet Autonomous Region People's Hospital
People needed: 3035
Starts: 2026-07-01
Expected to finish: 2028-12-31
Last updated by the study team: 2026-06-10

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Meeting the diagnostic criteria for severe acute mountain sickness (including high-altitude pulmonary edema [HAPE] and high-altitude cerebral edema [HACE]).
Aged 18 to 75 years.
Rapid ascent to an altitude above 2500 m within 72 hours prior to onset.

You may not qualify if…

History of severe cardiopulmonary diseases.
Pregnant women, patients with psychiatric disorders, inability to cooperate with treatment or follow-up, and patients with an expected survival of less than 6 months.
Patients with malignant tumors, severe hepatic or renal insufficiency, or immune system diseases requiring immunosuppressive therapy.

Where it is running

Xizang Autonomous Region People's Hospital — Lhasa, Tibet, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.